Intratumoral delivery of bortezomib: impact on survival in an intracranial glioma tumor model
Wang W, Cho HY, Rosenstein-Sisson R, Marín Ramos NI, Price R, Hurth K, Schönthal AH, Hofman FM, Chen TC
J Neurosurg. 2017 Apr 14:1-6. doi: 10.3171/2016.11.JNS161212. [Epub ahead of print]
View on: PubMed
Development of the Metronomic Biofeedback Pump for leptomeningeal carcinomatosis: technical note
Chen TC, Napolitano GR, Adell F, Schönthal AH, Shachar Y.
J Neurosurg. 2015 Aug;123(2):362-72. doi: 10.3171/2014.10.JNS14343. Epub 2015 May 8.
View on: PubMed
Effects of convection-enhanced delivery of bevacizumab on survival of glioma-bearing animals
Wang W, Sivakumar W, Torres S, Jhaveri N, Vaikari VP, Gong A, Howard A, Golden EB, Louie SG, Schönthal AH, Hofman FM, Chen TC.
Neurosurg Focus. 2015 Mar;38(3):E8. doi: 10.3171/2015.1.FOCUS14743.
View on: PubMed
Benefits of Metronomic Delivery
Clinical data supports the therapy value of intraventricular delivery of drugs into the Cerebrospinal fluid (CSF). Specifically, intraventricular drug delivery is indicated to improve drug efficacy by enabling the drug to reach the various regions of the brain following the cerebrospinal fluid circulatory pathway, thus providing an efficient and uniform drug infusion into the brain. Cognos Therapeutics is a leader in the design and development of a technologically advanced implantable pump, SINNAIS™, which includes a smart shunt adapted to deliver an adjustable volume and concentration of drugs to the ventricles in the brain. The Cognos Therapeutics smart shunt further includes features which enable physicians to utilize metronomic delivery of drugs, and obtain parametric data such as temperature, pressure and PH from the CSF. Notably, metronomic intraventricular drug delivery from Sinnais implanted pump may be applicable in the delivery of various new biotherapeutics to the brain, thus launching a new frontier in clinical therapy.
A Site-specific, Sustained-release Drug Delivery System for Aneurysmal Subarachnoid Hemmorhage
Daniel Hiinggi, Nima Etminan, Hans Jakob Steiger, Mark Johnson, Melissa Peet, Tom Tice, Kevin Burton, Bruce Hudson, Michele Turner, Angela Stella, Parissa Heshmati, Cara Davis, Herbert J. Faleck, Loch Macdonald
Randomized, Open-Label, Phase 1/2a Study to Determine
the Maximum Tolerated Dose of Intraventricular Sustained
Release Nimodipine for Subarachnoid Hemorrhage
(NEWTON [Nimodipine Microparticles to Enhance Recovery While Reducing Toxicity After Subarachnoid Hemorrhage]) model
Daniel Hanggi, MD; Nima Etminan, MD; Francois Aldrich, MD; Hans Jakob Steiger, MD; Stephan A. Mayer, MD; Michael N. Diringer, MD; Brian L. Hoh, MD; J Mocco, MD; Herbert J. Faleck, DO; R. Loch Macdonald, MD; on behalf of the NEWTON Investigators
Anti-miR delivery strategies to bypass the blood-brain barrier in glioblastoma therapy
Dong Geon, Kim Kang, Yun Jee, Heekyoung Yang, Eric G. Marcusson, Eunju Son, Kyoungmin Lee, Jason K. Sa, Hye Won Lee1, Do-Hyun Nam
Lymphomatous Meningitis in Primary Central Nervous System Lymphoma
Marc C. Chamberlain, M.D.
Best practices for the use of intracerebroventricular drug delivery devices
Irene Slavca,*, Jessica L. Cohen-Pfefferb, Sridharan GururanganC, Jeanne KrauserC, Daniel A. Limd, Marcos Maldaune, Christoph Schweringf, Adam J. Shaywitzh, Manfred Westphalf